A Randomized, Double-blind, Placebo-controlled, Single or Multiple Ascending Dose Phase I Clinical Trial to Evaluate the Safety, Tolerability, PK, PK-PD Relation of KD101 in the Fed State in Obese or Overweight Subjects
Latest Information Update: 08 Jul 2017
At a glance
- Drugs KD 101 (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Kwang Dong Pharmaceutical
Most Recent Events
- 05 Jun 2015 New trial record